This article first appeared on GuruFocus. Novo Nordisk A/S (NYSE:NVO) shares fell 5.96% in Copenhagen trading, as the Danish drugmaker used its London Capital Markets Day to lay out 2030 strategic ambitions, the first full reset under new CEO Mike Doustdar. The company said it wants revenue from 2026 to 2030 to grow at a compound annual rate "in line with industry peers," a group it defined to include Eli Lilly (NYSE:LLY), AstraZeneca, Gilead (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), AbbVie (NYSE:ABBV), among others. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.